Latest Insider Transactions at Immunovant, Inc. (IMVT)
This section provides a real-time view of insider transactions for Immunovant, Inc. (IMVT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Immunovant, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Immunovant, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 23
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,361
-1.33%
|
$126,469
$29.53 P/Share
|
|
Oct 23
2024
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,740
-1.89%
|
$79,460
$29.53 P/Share
|
|
Oct 23
2024
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,189
-2.31%
|
$92,481
$29.53 P/Share
|
|
Oct 16
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,188
-0.43%
|
$89,264
$28.79 P/Share
|
|
Oct 16
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,095
-0.91%
|
$254,660
$28.79 P/Share
|
|
Oct 16
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,271
-0.97%
|
$91,588
$28.79 P/Share
|
|
Oct 16
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,860
-0.87%
|
$80,080
$28.79 P/Share
|
|
Oct 09
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,460
-0.44%
|
$129,340
$29.56 P/Share
|
|
Oct 09
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,162
-1.5%
|
$149,698
$29.56 P/Share
|
|
Aug 21
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,295
-0.49%
|
$105,440
$32.08 P/Share
|
|
Aug 21
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,027
-0.34%
|
$96,864
$32.08 P/Share
|
|
Aug 21
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,768
-0.54%
|
$120,576
$32.08 P/Share
|
|
Aug 21
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,027
-0.41%
|
$96,864
$32.08 P/Share
|
|
Aug 21
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,068
-0.74%
|
$482,176
$32.08 P/Share
|
|
Jul 24
2024
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,456
-2.44%
|
$93,312
$27.76 P/Share
|
|
Jul 24
2024
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,813
-1.9%
|
$75,951
$27.76 P/Share
|
|
Jul 24
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,015
-1.19%
|
$108,405
$27.76 P/Share
|
|
Jul 17
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,123
-0.45%
|
$93,690
$30.09 P/Share
|
|
Jul 17
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,044
-0.2%
|
$91,320
$30.09 P/Share
|
|
Jul 17
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,505
-0.37%
|
$75,150
$30.09 P/Share
|
|
Jul 17
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,685
-0.42%
|
$260,550
$30.09 P/Share
|
|
Jul 17
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,867
-0.32%
|
$86,010
$30.09 P/Share
|
|
Jul 09
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,619
-0.45%
|
$129,332
$28.06 P/Share
|
|
Jul 09
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,527
-0.34%
|
$42,756
$28.06 P/Share
|
|
Jul 09
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,747
-1.34%
|
$132,916
$28.06 P/Share
|
|
May 22
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,247
-0.72%
|
$94,163
$29.65 P/Share
|
|
May 22
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,163
-1.54%
|
$468,727
$29.65 P/Share
|
|
May 22
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,042
-1.12%
|
$117,218
$29.65 P/Share
|
|
May 22
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,242
-0.94%
|
$94,018
$29.65 P/Share
|
|
May 22
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,247
-0.86%
|
$94,163
$29.65 P/Share
|
|
Apr 24
2024
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
7,239
-4.67%
|
$202,692
$28.9 P/Share
|
|
Apr 24
2024
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,261
-2.25%
|
$91,308
$28.9 P/Share
|
|
Apr 24
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,963
-1.14%
|
$110,964
$28.9 P/Share
|
|
Apr 17
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,280
-0.54%
|
$240,120
$29.37 P/Share
|
|
Apr 17
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,827
-1.38%
|
$284,983
$29.37 P/Share
|
|
Apr 17
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,253
-1.66%
|
$355,337
$29.37 P/Share
|
|
Apr 17
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,079
-1.58%
|
$988,291
$29.37 P/Share
|
|
Apr 17
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,115
-1.1%
|
$293,335
$29.37 P/Share
|
|
Apr 09
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,053
-0.23%
|
$32,643
$31.18 P/Share
|
|
Apr 09
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,689
-0.98%
|
$114,359
$31.18 P/Share
|
|
Apr 09
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,807
-0.44%
|
$149,017
$31.18 P/Share
|
|
Apr 02
2024
|
Douglas J. Hughes Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+8.26%
|
-
|
|
Apr 02
2024
|
Andrew J. Fromkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+10.12%
|
-
|
|
Apr 02
2024
|
Atul Pande Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+10.65%
|
-
|
|
Apr 02
2024
|
George V Migausky Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+8.51%
|
-
|
|
Apr 02
2024
|
Frank Torti Director |
BUY
Grant, award, or other acquisition
|
Direct |
120,400
+15.92%
|
-
|
|
Apr 02
2024
|
William L. Macias Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+12.47%
|
-
|
|
Apr 02
2024
|
Mark S. Levine Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+13.35%
|
-
|
|
Apr 02
2024
|
Jay S Stout Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+26.19%
|
-
|
|
Apr 02
2024
|
Michael Geffner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+27.51%
|
-
|